Massive Intoxication with 70 Tablets of Apixaban: A Case Report

Massive Intoxication with 70 Tablets of Apixaban: A Case Report

Apixaban is a direct oral anticoagulation agent that exerts its effect through the direct inhibition of factor Xa. We treated a case of massive intoxication with 70 tablets of apixaban and have presented the clinical course of the associated anti-Xa activities. A 49-year-old woman was admitted to th...

Full description

Bibliographic Details
Main Authors:	Tadahiro Kobayashi, Satoko Saito, Masayuki Takada, Kento Sakaguchi, Kazunori Takahashi, Ken Tanaka, Kaneyuki Kawamae, Masaki Nakane
Format:	Article
Language:	English
Published:	Karger Publishers 2023-09-01
Series:	Case Reports in Acute Medicine
Subjects:	antithrombin activity anti-xa activity apixaban intoxication prothrombin time-international normalized ratio
Online Access:	https://beta.karger.com/Article/FullText/533520

Similar Items

Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism
by: Sara Reda, et al.
Published: (2022-05-01)

Accidental apixaban intoxication in a 23-month-old child: a case report
by: Manon Launay, et al.
Published: (2020-12-01)

Chromogenic anti-Xa test: the ratio between heparin activity units and concentration of apixaban and rivaroxaban
by: E. V. Titaeva, et al.
Published: (2020-12-01)

Anticoagulant activity of apixaban can be estimated by multiple regression analysis
by: Naoko Unami, et al.
Published: (2020-12-01)

Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
by: Nina Haagenrud Schultz, et al.
Published: (2018-05-01)

Effects of rivaroxaban and apixaban on intimal hyperplasia in rabbits
by: Mustafa Baris Kemahli, et al.
Published: (2022-03-01)

Evaluation of the effect of apixaban using a viscoelastic coagulation assay with Russell’s viper venom reagent
by: Kaoru Suzuki, et al.
Published: (2021-05-01)

Hypoprothrombinemia in the compensated form of hepatosplenic schistosomiasis: further studies
by: Nora Manoukian, et al.
Published: (1988-08-01)

Binding modes of prothrombin cleavage site sequences to the factor Xa catalytic triad: Insights from atomistic simulations
by: Jiachen Li, et al.
Published: (2022-01-01)

Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements
by: Tamana Meihandoest, et al.
Published: (2021-09-01)

The role of autolysis loop in determining the specificity of coagulation proteases
by: L. Yang, et al.
Published: (2007-08-01)

Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events
by: Sofia Attelind, et al.
Published: (2022-09-01)

Traumatic Pseudoaneursym of Superficial Temporal Artery in an Octogenarian Patient Under Apixaban Therapy
by: Sertan Özyalçın, et al.
Published: (2020-02-01)

Apixaban anti-Xa level monitoring in treatment of acute upper extremity deep vein thrombosis for patient on chronic hemodialysis: a case report
by: Guillaume Roberge, et al.
Published: (2021-04-01)

Does atorvastatin therapy change the anti‐Xa activity in xabans‐treated patients with atrial fibrillation?
by: Ingrid Škorňová, et al.
Published: (2021-05-01)

A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs)
by: Tomas L. Lindahl, et al.
Published: (2017-07-01)

Apixaban
by: Gianluca Airoldi, et al.
Published: (2013-03-01)

Primary prophylaxis of venous thromboembolic disease with direct oral anticoagulants in patients with severe inherited thrombophilia
by: Evelien Krumb, et al.
Published: (2021-02-01)

Influence of Fucoidans on Hemostatic System
by: Mikhail V. Kiselevskiy, et al.
Published: (2013-07-01)

A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation
by: Nan Zhao, et al.
Published: (2022-03-01)

Comparative analysis of platelet depleted plasma prepared on the Roche 8100 automation line and manually centrifuged platelet poor plasma for routine coagulation assays
by: Mustafa A. Barbhuiya, et al.
Published: (2023-08-01)

Pharmacokinetics and Biologic Activity of Apixaban in Healthy Dogs
by: Noelle D. Herrera, et al.
Published: (2021-07-01)

Quick reference guide to apixaban
by: Hurst KV, et al.
Published: (2017-07-01)

Clinical study on the feasibility of new thrombus markers in predicting massive cerebral infarction
by: Xiaoxia Zhao, et al.
Published: (2023-01-01)

Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation
by: Kozue Ikeda, MD, et al.
Published: (2016-02-01)

Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis
by: Olivia S. Costa, et al.
Published: (2022-06-01)

Rectus sheath hematoma associated with apixaban
by: Kulothungan Gunasekaran, et al.
Published: (2017-08-01)

Value of novel thrombotic markers for predicting occurrence of the malignant cerebral artery infarction: a prospective clinical study
by: Xiaoxia Zhao, et al.
Published: (2023-11-01)

Management of Therapeutic-intensity Unfractionated Heparin: A Narrative Review on Critical Points
by: Isabelle Gouin-Thibault, et al.
Published: (2024-07-01)

Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants
by: Myrthe M. A. Toorop, et al.
Published: (2020-05-01)

Sangrado hepático espontaneo en paciente tratado con Apixaban
by: Ignacio Ramil Freán, et al.
Published: (2019-10-01)

Preparation of Apixaban Solid Dispersion for the Enhancement of Apixaban Solubility and Permeability
by: Juseung Lee, et al.
Published: (2023-03-01)

In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra
by: Herm Jan M. Brinkman, et al.
Published: (2022-07-01)

Case report: Drug-drug interaction between alectinib and apixaban in NSCLC
by: J.L. Gulikers, et al.
Published: (2022-09-01)

Reversible Neurological Adverse Reaction to Apixaban
by: Eduardo Rodrigues Cernadas, et al.
Published: (2021-04-01)

Prevention of venous thromboembolism with rivaroxaban and apixaban in orthopedic surgery
by: Antonijević Nebojša, et al.
Published: (2020-01-01)

Hypersensitivity reaction to rivaroxaban with a successful switch to apixaban: A case report
by: Keyhan Mohammadi, et al.
Published: (2024-08-01)

Antithrombin III: Plasma Activity and Reference Range Among Nigerian Blood Donors
by: Vincent Oluseye Osunkalu, et al.
Published: (2015-01-01)

Non-valvular atrial fibrillation: impact of apixaban on patient outcomes
by: Ioannou A, et al.
Published: (2017-11-01)

Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways
by: Andrea Huppertz, et al.
Published: (2019-08-01)